Articles tagged "Mycophenolate mofetil"

2022 American Transplant Congress
Reduced Dose Mycophenolate Does Not Increase the Risk of Rejection Following Renal Transplantation
L. Bowman¹, A. Webb¹, S. Desai², D. Patino³, V. Subramanian⁴, S. Mohammed⁵, M. Gosselin⁶, K. Robichaux⁵, J. Buggs⁴, A. Kumar⁷
¹Transplant Pharmacy, Tampa General Hospital, Tampa, FL, ²Western University of Osteopathic Medicine, Pomoma, CA, ³Michigan State University College of Human Medicine, Lansing, MI, ⁴Transplant Surgery, Tampa General Hospital, Tampa, FL, ⁵University of South Florida, Tampa, FL, ⁶University of Tampa, Tampa, FL, ⁷Morsani College of Medicine, University of South Florida, Tampa, FL
*Purpose: Mycophenolic acid (MPA) exposure correlates inversely with the risk of acute rejection; however, evidence also suggests that systemic MPA exposure also determines the extent…
2022 American Transplant Congress
The Effect of Tacrolimus and Mycophenolic Acid on Torque Teno Virus Loads in Kidney Transplant Recipients
A. van Rijn, S. Meziyerh, D. van der Helm, T. van Gelder, A. Kroes, J. de Fijter, D. Moes, J. Rotmans, A. de Vries, M. Feltkamp
Leiden University Medical Center, Leiden, Netherlands
*Purpose: Measuring immune function in kidney transplant recipients (KTRs) remains challenging given the precarious balance between over- and underimmunosuppression. This is primarily due to high…
2022 American Transplant Congress
Mycophenolate Mofetil-Related Diarrhea and Beta-Glucuronidase Activity Following Kidney Transplantation
G. C. Onyeaghala¹, S. Elmer¹, D. Schladt¹, P. Yang¹, M. Wagner², L. Teigen², M. Al-Kofahi², B. Wu², W. Guan², C. Staley², S. Riad², A. Matas³, R. Remmel², W. Oetting², C. R. Dorr¹, P. Jacobson⁴, A. Israni¹
¹Nephrology, Hennepin Healthcare Research Institute, Minneapolis, MN, ²University of Minnesota, Minneapolis, MN, ³University of Minnesota Medical School, Minneapolis, MN, ⁴Univ of MN, College of Pharmacy, Minneapolis, MN
*Purpose: The treatment of mycophenolate mofetil (MMF)-related diarrhea in kidney transplants recipients often involves dose reductions, which may result in less effective immunosuppression. We hypothesize…
2022 American Transplant Congress
Covid-19 Vaccination Response In Tacrolimus Treated Kidney Transplant Recipients With And Without Mycophenolate Mofetil: Follow-up Of A Randomized Controlled Trial
Z. Al Fatly¹, M. G. Betjes¹, A. L. Messchendorp², J. S. Sanders², M. E. Reinders¹, M. M. Kho¹, A. E. de Weerd¹
¹Department of Internal Medicine, Erasmus MC Transplant Institute University Medical Center, Rotterdam, Netherlands, ²Department of Internal Medicine, Groningen Medical Center, Groningen, Netherlands
*Purpose: To investigate the effect of mycophenolate mofetil (MMF) on SARS-CoV-2 vaccination response in kidney transplant recipients using the standard immunosuppressive regimen of tacrolimus (TAC)…
2022 American Transplant Congress
Clinical Outcomes In A Large Transplant Cohort Hospitalized With COVID-19: Mycophenolate Mofetil (MMF) Utilization And Mortality Trends
R. L. Gottlieb¹, M. Askar², L. Chen³, A. Chandak⁴, E. Mozaffari³, M. Thrun³, R. Haubrich³
¹Baylor Scott & White Research Institute, Dallas, TX, ²Baylor University Medical Center, Dallas, TX, ³Gilead Sciences, Foster City, CA, ⁴Certara, New York, NY
*Purpose: To characterize demographics, treatment patterns, and outcomes among 3,998 transplant patients hospitalized for COVID-19 over 16 months of the pandemic (May ’20-Aug ’21).*Methods: Adult…
2022 American Transplant Congress
Effect of Mycophenolate Mofetil Dosing on Antibody Response to SARS-CoV-2 Vaccination in Heart and Lung Transplant Recipients
J. Mitchell¹, T. P. Chiang¹, J. Alejo¹, A. Chang¹, A. Abedon¹, R. Avery¹, A. Tobian¹, A. Massie¹, M. Levan¹, D. Warren¹, J. Garonzik-Wang², D. Segev¹, W. Werbel¹
¹Johns Hopkins University, Baltimore, MD, ²University of Wisconsin-Madison, Madison, WI
*Purpose: Mycophenolate mofetil (MMF) use is associated with decreased antibody response to the SARS-CoV-2 mRNA vaccine series in heart and lung transplant recipients (HLTRs). Higher…
2022 American Transplant Congress
Immunosuppressants Alter Lymph Node Architecture and Create Distinct Microbiome Footprints
S. J. Gavzy¹, R. Lakhan², J. Iyyathurai², V. Saxena², L. Li², B. Ma², E. Mongodin², J. S. Bromberg²
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Maryland, Baltimore, MD
*Purpose: There are complex interactions among immunosuppressants, antibiotics, and the gut microbiome on the host immune system. Microbiota can alter lymph node (LN) structure and…
2022 American Transplant Congress
Reduced Enterohepatic Recirculation of Mycophenolate and Lower Blood Concentrations Are Associated with the Stool Bacterial Microbiome
P. A. Jacobson¹, A. Saqr¹, B. Carlson¹, C. Staley², A. Rashidi³, S. Holtan³, M. Al-Kofahi¹, T. Kaiser², M. MacMillan⁴, J. Young⁵, N. El Jurdi³, D. Weisdorf³, A. Khoruts⁶
¹Univ of MN, College of Pharmacy, Minneapolis, MN, ²Univ of MN, Dept of Surgery, Minneapolis, MN, ³Univ of MN, Divison of Heme/Onc Transplant, Minneapolis, MN, ⁴Univ of MN, Pediatric Heme/Onc Transplant, Minneapolis, MN, ⁵Univ of MN, Divison of Infectious Diseases, Minneapolis, MN, ⁶Univ of MN, Division of Gastroenterology, Hepatology and Nutrition, Minneapolis, MN
*Purpose: Mycophenolate mofetil (MMF) is an important immunosuppressant used after allogeneic hematopoietic cell transplant (HCT). Blood concentrations of mycophenolic acid (MPA) are highly variable and…
2022 American Transplant Congress
Use of Dd-cfdna to Guide Tapering of Immunosuppression Therapy in Kidney Transplant Recipients
G. Osuchukwu¹, A. Trevino¹, L. Beretich², S. McCormick², N. Kaur², R. White², P. Gauthier²
¹Victoria Kidney and Dialysis Associates, Victoria, TX, ²Natera, Inc., Austin, TX
*Purpose: Continuous administration of immunosuppressive therapy (IST) is required to avoid allograft rejection in transplant recipients. However, these therapeutic interventions can lead to significant side…
2022 American Transplant Congress
Evaluating the Risk and Benefit of Once Daily Delayed Release Mycophenolate in Pediatric Kidney Transplant Recipients
L. Maestretti¹, A. McGrath¹, A. Fong¹, A. Brubaker², A. Gallo³, P. Grimm³, A. Chaudhuri³
¹Pediatric Kidney Transplant, Stanford Children's Health, Palo Alto, CA, ²Transplant Surgery, Stanford University, Palo Alto, CA, ³Stanford University, Palo Alto, CA
*Purpose: Medication non-adherence continues to particularly affect adolescent kidney transplant recipients. Standard immunosuppressive regimen at our center includes tacrolimus, and mycophenolate with or without steroids.…

1
2
3
…
6
Next Page »